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ABSTRACT 
Influenza virus causes a contagious respiratory illness in humans that poses a major 
public health threat, especially to vulnerable populations such as children and adolescents, who 
have less mature immune systems. Influenza infections are responsible for over 200,000 
hospitalizations and over 3,600 deaths a year.  The influenza vaccine is the best form of 
prevention from influenza illness due to the vaccines ability to elicit an antibody response 
without causing illness.  Currently, there are two types of influenza vaccines available to children 
and adolescents, the inactivated influenza vaccine (IIV) and the live attenuated influenza vaccine 
(LAIV). The present study was designed to compare the immunogenicity of the two vaccines in 
pediatric participant’s ages 3 to 17 years. We hypothesized that the LAIV vaccine would produce 
an increased breath and enhanced antibody response to influenza vaccination compared to the 
IIV vaccine.  Results from this study suggest that IIV was superior compared to LAIV at 
eliciting immune responses following vaccination.  However, potential limitations include the 
fact that current assays measure immune responses in peripheral blood only and may not reflect 
mucosal immunity. Further, due to issues with the H1N1 virus strain in the LAIV vaccine, these 
results need to be confirmed in a season where LAIV vaccine is immunogenic (2015-16). 
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1.0  INTRODUCTION 
Influenza virus contains a segmented negative-sense RNA genome and belongs to the 
family Orthmyxoviridae [1, 2].  This virus is a zoonotic pathogen that infects both humans and 
animals.  Influenza season for humans generally begins in October and ends in March of the 
following year, with peaks in infections in December and February [3].  In humans, influenza 
virus manifests as a highly contagious, respiratory illness that is transmitted person to person by 
droplets in the air (coughing, sneezing or talking up to six feet away), or by touching a surface or 
object that is contaminated with virus and then touching their mouth, nose or eyes [4].  It can 
also be transmitted from birds to humans via a mammalian intermediate host [4]. Influenza virus 
affects everyone in the population, generally causing mild illness that does not require medical 
intervention [5].  In children, adults over age 65, and those with certain medical conditions, 
influenza virus can cause serious illness leading to hospitalization or even death [5]. In the 
Unites States, this virus is responsible annually for over 200,000 hospitalizations and 3,600 
deaths, and is responsible for the most deaths by a vaccine-preventable disease [6-8] . 
Influenza virus can be treated with anti-viral medications, but these medications are not 
often used in a preventative manner.  Some antivirals such as Tamiflu can be used 
prophylactically in instances of an outbreak in the community or if someone in your house is sick 
and you want to try to prevent transmission. Currently, vaccines are the best prevention method 
for influenza virus infection and there are two types of vaccines are available: the live attenuated 
 2 
influenza vaccine (LAIV) and the inactivated influenza vaccine (IIV) [6].  LAIV is administered 
intranasally and is recommended for people ages 2-49 years, whereas IIV is administered 
intramuscularly and is recommended for people ages 6 months and older [9].  Currently there is 
no official preference for LAIV over IIV; although children have generally been administered 
LAIV due to the presumption that a live attenuated vaccine will result in longer lasting and 
increased breadth and maturation of the immune response.  The Center for Disease Control and 
Prevention (CDC) stresses the importance of an annual influenza vaccine for everyone over the 
age of 6 months.  
1.1 INFLUENZA VIRUS 
Influenza viruses are classified as type A, B or C.  Type A viruses are classified 
according to their surface glycoproteins, hemagglutinin (H or HA) and neuraminidase (N or NA) 
[1, 3].  Currently there are 18 H (H1-H18) and 11 N (N1-N11) identified subtypes for the 
influenza A virus [2, 3].  The most common circulating human strains of influenza A in the 
Unites States are H1N1 and H3N2 [3].  Influenza A viruses are able to cause both epidemics and 
pandemics.  Type B influenza viruses are known to cause seasonal epidemics, and different 
linages are utilized in the creation of vaccines.  Type C viruses only cause mild respiratory issues 
and are not known to cause epidemics or pandemics. Therefore, type C influenza is not used in 
preventative medicine such as vaccines [8]. 
Influenza A and B viruses are named according to their type, geographic origin, strain 
number, and year of isolation.  Influenza A virus is further classified by subtype, and this 
subtype is how we typically refer to the virus (i.e. H1N1) [3].  An example of a type A virus 
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strain would be: A/California/7/2009(H1N1) (Figure 1). Influenza B is not divided into subtypes 
like type A, instead they are classified and referred to by lineage.  An example of a Type B virus 
would be B/Brisbane/60/2008(B/Victoria lineage) [3].  A culmination of different influenza A 
and B viruses are used in seasonal vaccines to prevent against predicted circulating strains each 
year.  Predictions of future circulating strains are based off of patterns from previous years [10]. 
 
 
Figure 1. Influenza Nomenclature.  
This figure depicts how influenza A and B viruses are named.  The virus is named according to the 1) virus type 
(determined by the nuclear material), 2) geographic origin (where the virus was first isolated) 3) specific stain 
number, and 4) year of isolation (representative of the year the stain first emerged). Influenza A viruses are also 
identified by their virus subtype using the two surface proteins (Hemagglutinin and Neuraminidase). 
 
Influenza virus variations are due to the virus poor replication skills. Influenza virus 
replication is inherently error-prone, resulting in mutations that arise as a result of the virus 
replication cycle.  Thus, over time, we have seen an evolution of influenza variants emerge. 
Influenza virus initiates infection by the attachment of the hemagglutinin protein on the surface 
of the virus binding to the sialic acid receptors on the surface of human respiratory tract cells. 
Once attached, the influenza virus is able to enter the cell via endocytosis.  Once inside the cell, 
the virus genome is released, and is transported to the cell nucleus for replication of the RNA 
genome into a DNA template. The newly created DNA genome segments are transported into the 
cytoplasm, where they are translated into the proteins needed to create a new progeny virus. The 
newly produced viral proteins assemble at the cell membrane where they are released from the 
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cell.  This cleavage even involves  release of the hemagglutinin and sialic acid receptors by 
neuraminidase, producing new progeny virions that are free to infect neighboring cells [8]. 
 
 
Figure 2. Influenza virus binding to respiratory tract cells[3].  
The influenza virus attaches to the respiratory track via the glycoprotein on the surface of the virus.  The 
hemagglutinin binds to the sialic acid on the respiratory track and is then endocytosed into the cell. 
1.1.1 Antigenic Shift and Drift 
Variations in the H and N of influenza viruses are commonly referred to as antigenic shift 
and drift, are what cause epidemics and pandemics, respectively.  Antigenic drift refers to 
frequent minor errors in virus replication, known as point mutations, on the H and N surface 
glycoproteins of the virus.  These mutations lead to epidemics in a population, mainly the result  
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of the naivety of the immune system of the infecting population [2, 10].  Antigenic shift occurs 
through major changes to the H or N proteins after reassortment of two or more virus genomes 
leading to new subtypes and is responsible for pandemics.  These shifts in surface protein are due 
to an exchange of genetic segments between different virus strains, and generally involve the 
recombination of strains from an animal host with one from a human.  While recombination 
events may occur in theory within a human host, those to date that have been responsible for the 
historical pandemics have been the result of avian and human or avian and avian recombination 
events. [10].  Influenza pandemics are introductions of new viruses from animal into human 
species, such as from birds or pigs.   Pandemics stretch widely across a geographic region, or 
even a continent, affecting higher proportions of a population over a short period of time. 
Pandemics have been of particular concern due to zoonosis which is the ability of avian 
influenza strains to jump species and now infect the human population.  An influenza A virus 
originating in birds cannot directly infect human cells due to the lack of the avian-specific 
receptors.  The same is true for influenza A viruses in humans being segments of both viruses 
[10].  However, through an intermediate host that has receptors for both species, the two virus 
strains are able to reassort and create a new virus strain. For example, pigs have receptors for 
both avian and human virus stains in their throats, allowing reassortment of the genetic material 
to create a new virus that can infect the human population [10]. 
1.1.2 Epidemiology and Transmission 
Influenza has been plaguing the human population for over 6,000 years and it wasn’t 
until the 1930’s that humans discovered what was causing these disease [11, 12]. Researchers 
believe that humans inherited influenza infection following the domestication of animals and the 
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establishment of organized settlements.  The close quarters of the settlements with livestock 
allowed the influenza virus to easily jump species from birds to humans, through pigs as the 
intermediate host [11, 12].   
The first documented influenza pandemic was in the 1580s [11, 12].  This pandemic 
spread from lower Asia to Northern Africa.  The disbursement of those infected by the virus was 
speculated to be due in part to troops’ migration to fight the Dutch in the Spanish Netherlands. In 
that period, people did not know that an influenza pandemic was occurring, but were 
overwhelmed with the number of people falling ill with the disease. 
In the 1700s it was believed that influenza outbreaks were caused from miasmas 
(unpleasant odors) or bad air [11, 12]. Later, it was hypothesized that it was bacteria, not 
miasmas, that caused influenza outbreaks [13].  There were major influenza epidemics recorded 
between 1830 and 1848.  The 1830-1831 influenza epidemic may have originated in China, then 
advanced westward out of Russia into Europe in 1833. In 1836-1837, influenza spread 
southward, and in 1847 it swept through the Mediterranean to Southern France and into the rest 
of Western Europe [12].  The first pandemic of the modern world occurred in 1889-1890, most 
likely due to advancements in transportation and trade (travel by train and boat).  This pandemic 
was first recorded in St. Petersburg, Russia and quickly spread throughout the Northern 
Hemisphere.  The virus had a high infection rate (25% of the population) and rarely caused death 
[12].  
The 20th century brought about the most devastating influenza pandemics, killing more 
people worldwide than the Great War (~50 million people) [13]. The most notable pandemic in 
the US began in 1918 and was the subtype H1N1.  The virus was of avian origin and spread to 
other parts of the world including Europe, and Southern and Eastern Africa and Asia. This 
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pandemic was especially devastating to the younger population [11, 13].  The pandemic was 
referred to as the “Spanish flu” because during World War I, the virus spread from France to 
Spain, at which time it was first reported.  At the time, Spain was a neutral country and was able 
to freely report the outbreak of the influenza infection.  Other countries did not have the same 
freedom of press and were unable to report the pandemic in a timely manner.  Although it is 
speculated that the 1918 influenza pandemic originated in British army camps in Europe, it will 
forever be known as the Spanish Flu.  In the 1930s, while conducting studies on pigs, scientist 
were able to isolate influenza and discovered the true cause of influenza outbreaks were due to a 
virus, not a bacteria like previously hypothesized [11, 13]. Two more notable pandemics 
followed in 1957 (H2N2) and 1968 (H3N2).  The H2N2 pandemic, otherwise referred to as the 
Asian flu pandemic, originated in China in early 1956 and lasted until 1958.  It spread from 
China to Singapore early into 1957, then to Hong Kong and the US by June of that year. Total 
deaths approached 70,000 in the US, with deaths worldwide estimated to be from 1 to 4 million. 
Today, this strain is extinct, but the Asian flu strain evolved via antigen shift into H3N2 and 
caused a milder pandemic from 1968-1969.  Both pandemic strains clearly arose from 
reassortment between human and avian viruses (compared to the 1918 strain, which was entirely 
avian) [11]. Influenza pandemics of the 20th century exceeded a total death toll of one million 
worldwide [2]. 
In March of 2009, the first pandemic of the twenty-first century emerged as an H1N1 
virus.  Air travel provided the accessibility needed  help the virus spread very quickly and WHO 
recognized this virus as the most widespread pandemic after it was identified on at least two 
different continents [2].  This pandemic seemed to have the greatest effect on children and young 
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adults.  Researchers speculated that the older population had some immunity due previous 
exposure to the 1957 epidemic [2].   
 
 
 
Figure 3. Pandemics of influenza.  
Timeline for major flu pandemics from 1918 to 2016.  Virus strains with arrows indicate the virus strain is still in 
circulation. 
 
 
 
 
1.1.3 Pathogenesis 
Influenza virus infects many species, including birds, pigs, and humans.  In birds, the 
virus replicates in the digestive tract and is evacuated through the feces [10].   In pigs the virus 
replicates in the through and is transmitted through close contact such as touching noses and 
dried mucus [14]. In humans, influenza virus infects the upper and lower respiratory tract via 
inhalation of infected aerosol droplets or through saliva [10].  Symptoms of influenza include: 
respiratory tract infection, fever, myalgia, sore throat, and cough, all of which are elicited due to 
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cytokine responses to infection [10].  The influenza virus has an incubation period of one to two 
days, and an infected individual is able to transmit one day prior to sign of symptoms and 5 to 7 
days after onset of symptoms [5].  Children can remain contagious for up to 10 days after 
infection [3].  Complications with influenza, such an pneumonia, are due to loss of natural 
epithelial barriers during influenza infection [10].   Influenza infections generally resolve 
themselves within a week thanks to the innate and acquired immune responses.  However, 
~3,600 people annually in the United States do not recover and die from the disease [8].  
1.2 TREATMENT AND PREVENTION 
1.2.1 Treatment 
Antiviral drugs can be given to those already infected with the influenza A or B virus, or 
can be taken as a prophylactic if a known outbreak of influenza occurs in the community.  There 
are currently two different types of FDA-approved antivirals on the market, neuraminidase (N) 
inhibitors and matrix 2 (M2) channel Inhibitors [8].  N inhibitors, including zanamivir and 
oseltamivir, block the neuraminidase enzymes synthesized by the influenza virus, interfering 
with the viruses’ ability to release virions from the cell [10].  Oseltamivir is administered orally 
and zanamivir is administered via inhalation.  If taken within 48 hours there can be a reduction in 
influenza-related symptoms by approximately one day [10].  Examples of M2 channel inhibitors 
are amantadine and rimantadine.  Once the virus is inside the host cell, these drugs block the 
transmembrane M2 ion channel proteins that are responsible for the uptake of protons, rendering 
the virus unable to release its genetic material into the cell for replication. Today, M2 channel 
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inhibitors are not used much due to the rapid development of resistance; N inhibitors are slightly 
better but, still seeing resistance [15].  
1.2.2 Prevention 
Vaccines are the most effective line of prevention against seasonal influenza viruses [9]. 
Vaccines allow the body to produce specific antibodies and T cell responses so that later 
exposure to some influenza viruses result in protection from the virus or less severe symptoms 
through immune memory stimulation [10].  The American Academy of Pediatrics (APA) along 
with Center for Disease Control and Prevention (CDC) recommend that people ages 6 months or 
older be vaccinated with the seasonal flu vaccine annually to help reduce the spread of influenza 
virus [9].   
 Currently, there are two types of vaccines administered to prevent influenza, the live 
attenuated influenza vaccine (LAIV) and the inactivated influenza vaccine (IIV) [9].  These 
vaccines provide protection from the influenza virus by exposing the immune system to a 
specific influenza strain [10]. When virus infection is first detected by the immune system, innate 
immune response develops rapidly and controls virus during the early stages of virus infection. 
This involves recognition of foreign antigen through mechanisms that are not antibody-specific.  
However, innate immunity also involves the secretion of cytokines that serve to stimulate and 
recruit cells involved in the adaptive immune response.  When immune memory is present 
(either from prior vaccination or infection) the antigen-specific adaptive response is faster than in 
patients seeing the antigen for the first time (primary adaptive immunity).  Adaptive immune 
responses involve generation of antigen-specific B cell responses that secrete antibodies to 
neutralize, prevent virus from infection naïve cells[10].  Alternately, activation of T lymphocytes 
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occurs when antigen is taken up and presented in the form of viral-derived peptides to T 
lymphocytes by antigen presenting cells. Through the production of cytokines, T helper cells 
contribute to B cell proliferation and differentiation to plasma cells, activation and proliferation 
of virus-specific cytotoxic T lymphocytes (CTLs) leads to killing of virus infected target 
cells[10]. Activation of the adaptive immune response occurs through peptides derived from 
viral proteins, which are presented on antigen-presenting cells to the T lymphocytes. Helper T 
cells, through the production of cytokines, contribute to B cell proliferation and differentiation to 
plasma cells, and to the activation and proliferation of virus-specific cytotoxic T lymphocytes 
(CTLs).  
Both types of vaccines, LAIV which is a live, replicating virus, and IIV, which is a 
mixture of viral proteins, are capable of eliciting immune memory in patients following 
vaccination.  By eliciting and stimulating immune memory through vaccination, it is presumed 
that patients, if and when exposed to influenza later in the season, will either not get infected or 
have a lessened infection and disease course. [10]. 
 The LAIV vaccines contains live virus that cannot grow well in a host, but 
replicates enough to elicit an immune response [10]. The viruses in this vaccine are made less 
virulent by heating the virus at nonphysiological temperatures during propagation [10].  This 
vaccine is administered intranasally and is approved for people 2-49 years of age [9].  LAIV 
vaccines can contain either three (trivalent) or four (quadrivalent) virus stains.  The quadrivalent 
LAIV vaccine contains two strains of influenza A virus and two types influenza B virus.  There 
is no influenza C virus in vaccines.  For example, the quadrivalent LAIV vaccine used in the 
seasonal 2014-2015 vaccine as part of this study contained: A/California/7/2009 (A/H1N1), 
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A/Texas/50/2012 (A/H3N2), B/Massachusetts/02/2012 (B/Yamagata lineage), and 
B/Brisbane/60/2008 (B/Victoria lineage). 
  IIV vaccines contain viruses that have been “killed” by chemical or physical 
means.  In the case of the quadrivalent IIV vaccine used in this study by Sanofi, the virus is 
produced and inactivated by a combination of heat and formaldehyde x 2 iterations, followed by 
purification to remove the chemicals and concentrate the virus.  Finally, the viral membrane is 
disrupted so that all viral proteins are available to the immune system upon vaccination.  This 
preparation is therefore noninfectious and free from harmful reagents. [10].  The IIV vaccine is 
administered intramuscularly and is approved for anyone over the age of six months [9].  Similar 
to LAIV, IIV can be trivalent or quadrivalent. LAIV and IIV vaccines have identical virus strains 
that change seasonally.  
The major limitation to the current vaccine strategy is due to antigenic shift and drift,  
[10]. Each year a new vaccine is created based off a prediction of the circulating strains for the 
prior year.  Beginning in January of each year, the World Health Organization (WHO) and 
experts from 82 different countries get together and decide what circulating stains should be 
placed in the vaccine for the upcoming flu season. This decision on strain is made while still in 
the midst of the current influenza season and 9 months prior to the next vaccination season.  
Thus is partially relies on prediction of what strains will circulate in the next season.  For this 
reason, there is never a guarantee that the vaccine will be completely matched to the next season 
strains.  [16]. Once decided, the predicted strains are sent to the vaccine manufactures that then 
make and test the vaccine for distribution to the public.  Vaccines are produced and ready to 
distribute for the influenza season by late August to early October [16].  Clearly, new and faster 
methods for vaccine production are needed to improve this process.   
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Vaccines are also analyzed each year for their effectiveness, measuring how well the 
influenza vaccine protected against the influenza illness. Effectiveness of the influenza vaccines 
are determined annually by the CDC utilizing randomized control trials [3].  Two main factors 
contribute to the effectiveness of the influenza vaccine, 1) the characteristics of the person being 
vaccinated (age and current health conditions) and 2) how closely the vaccine strains match with 
the circulating viruses.  The protective benefit of the influenza vaccine is low in years when the 
vaccine does not match the circulating stains, however there is still some protection [3].  During 
influenza seasons where the vaccine is a close match to the circulating viruses, protection 
averages between 50-60% among the overall population [3].   
1.3 PUBLIC HEALTH SIGNIFICANCE 
In the United States, seasonal influenza virus infections are the highest cause of death 
from a vaccine preventable disease [7].  Influenza infections are highly contagious, especially in 
our vulnerable populations, such as children/adolescents, and are responsible for more than 
200,000 hospitalizations and 3,600 deaths each year [6, 7, 10].  In the United States, Direct 
medical cost associated with influenza virus annually averages ten billion dollars [17]. Overall, 
Influenza virus-attributed economic costs annually in the United States average 87.1 billion dollars 
[17]. This overall burden can be greatly reduced through prevention by vaccination.  There are 
currently two types of influenza vaccines on the market; LAIV and IIV.  These vaccines can aid in 
reducing a person’s risk for disease and reduce transmission. The financial burden endured due to 
time lost to work and cost of medical bills can all be reduced with the low cost of the influenza
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vaccine. Each year a new influenza vaccine is created predicating circulation virus 
strains for the next influenza season.  Therefore ensuring annual vaccination of all able people 
ages 6 months is imperative in producing herd immunity to protect those who are unable to be 
vaccinated.  Knowing which virus strains and vaccine type are most efficient in a certain 
population is pivotal to the reduction of influenza Infections.   
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2.0  STATEMENT OF PROJECT 
 Determination of the most effective seasonal influenza vaccine and providing the vaccine 
to the population at large can reduce the number of cases of influenza infection and death 
annually.  This in turn reduces the significant health care burden and costs associated with 
influenza.  The goal of this study was to determine whether LAIV would produce an increased 
breath and antibody response compared to IIV vaccination in children 3-17 years of age.  
Historically, we can use hemagglutinin antibody inhibition (HAI) assay and microneutralization 
(MN) assay to measure antibody titers in children pre and post seasonal influenza vaccine 
inoculation to determine if vaccination elicited an immune response capable of generating 
immune memory.  Our hypothesis was that LAIV would produce an increased breadth and 
enhanced antibody response to circulating influenza strains in comparison to IIV in a cohort of 
children, ages 3-17 years old.  This hypothesis was tested using the following specific aim: 
 
Aim 1: To compare antibody responses elicited by LAIV and IIV vaccination in 
pediatric patients, ages 3-17 years old. To address this aim, an HAI assay and an MN assay 
were optimized for use with children’s serum samples.  The HAI assay can detect antibody titers 
to virus in human serum. This assay can verify if antibodies have been created [10].   The MN 
assay measures the highest dilution of antibodies that neutralize virus replication, which is 
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important in understanding the antigenic structure of the virus and the immune response elicited 
[10]. 
 
 
 17 
3.0  METHODS 
This study was sponsored by the Centers for Disease Control and Prevention (CDC) and 
was initiated after considering preferential recommendation of influenza vaccination using the 
LAIV over the IIV in children 2 to 8 years of age.  The University of Pittsburgh worked in 
collaboration with the Children’s Hospital of Pittsburgh Primary Care Office, UPMC Shadyside 
Family Health Center, and UPMC Lawrenceville Family Health Center to collect specimen 
samples.   
Following Institutional Review Board (IRB) consent, and receiving protocols from the 
CDC, all experiments for this study were performed in the biosafety level 2+ laboratory in the 
Center for Vaccine Research (CVR) at the University Of Pittsburgh.  All participants in the study 
received quadrivalent LAIV or IIV and had blood drawn on three separate time points: Day 0 
(prior to vaccination) Day 7, and Day 21 following vaccination.  Blood samples were processed 
for serum, plasma, and PBMC.  Processing was performed under a class II biosafety cabinet 
using vesphene for decontamination.  Once all samples where processed they were sent to CDC 
Contracting Lab, Battelle, Inc., and CDC for analysis.  
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3.1 STUDY PARTICIPANTS 
All participants in this study were recruited from August to December of 2014, from the 
Children’s Hospital of Pittsburgh Primary Care Office, UPMC Shadyside Family Health Center, 
or UPMC Lawrenceville Family Health Center, Pittsburgh, PA. Recruitment methods included 
letters, phone calls, in person recruitment, and flyer/poster advertisements.  Those contacted by 
letter were sent inclusion criteria along with study activities and numbers to contact if interested.  
Anyone who was contacted by phone or in person was read a script explaining the participant’s 
rights upon involvement in the study and questions regarding inclusion and exclusion. These 
surveys were then sent to the appropriate research assistant for potential enrollment.  Children 
between the ages of 3 and 17 years were recruited for the study and underwent a health 
evaluation to determine eligibility.  If applicable, children were given a unique identification 
number and segregated into groups based on age (3-8 years vs. 9-17 years). Children were 
further segregated based on the chosen vaccine type (LAIV vs. IIV).  There were 173 
participants recruited, 23 of which did not complete all three visits required for the study.  Of the 
150 participants that finished the study, there were 60 participants for the 3 to 8 years age group; 
20 participants chose to receive quadrivalent IIV and 40 participants chose the quadrivalent 
LAIV (shown in Table 1).  Ninety participants were recruited into the 9-17 year age group; 33 
chose to receive quadrivalent IIV and 57 chose the quadrivalent LAIV. 
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          Table 1. Pediatric Patients Recruited for the 2014-2015 Vaccine Study. 
 
3.1.1 Inclusion 
Eligible participants for the study had to meet several requirements.  Participants must be 
between the ages of 3 to 17 upon enrollment, not turning 18 prior to completion of the required3 
visits; willing to receive the seasonal influenza vaccine for the 2014 year at one of the study 
enrollment sites; and meet all inclusion criteria as listed in the IRB.  Participants were given the 
choice of which quadrivalent vaccine they would like to receive, LAIV or IIV.  Participants also 
had to provide documentation of the vaccine they received the previous year (2013-14 influenza 
season).  
3.1.2 Exclusion 
There were also several criteria that excluded children from participating in the study. 
These included any participant/parent unable or unwilling to complete all required study 
activities, such as informed consent paperwork; or participants that were known to have a 
compromised immune system, or that were taking immunosuppressing medication such as 
steroids.  If children had not participated in the 2013-2014 vaccination study, or had already 
received a vaccine for 2014-2015 season, they were unable to be enrolled in the study.  Other 
 2014-2015 
Vaccine 
Completed 
Day 0 
Dropouts Total  
3-8 YEAR 
OLDS 
LAIV 40 8 48 
IIV 20 7 27 
9-17 YEAR 
OLDS 
LAIV 57 23 80 
IIV 33 0 33 
Total Participants: 150 23 173 
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exclusions from the study included not meeting the weight requirement (<17kg), pregnancy, or 
an allergy to influenza vaccines.  
3.2 BLOOD COLLECTION  
Once a child was deemed eligible for the study, a blood sample was taken at the 
enrollment site prior to vaccination (Day 0).  Two more blood samples were taken from the 
participants on Day 7 and Day 21 post vaccination for a total of 3 blood draws per child.  The 
blood samples, labeled with a unique identifier, were then sent to the Center for Vaccine 
Research (CVR) within four to six hours of each blood draw for further sample extraction.  
Blood samples were processed for plasma and peripheral blood mononuclear cells (PBMC) from 
D0, D7, and D21 blood draws.  Serum from D0 and D21 blood draws were collected using a 
special separation tube.  
3.3 BLOOD PROCESSING 
3.3.1 Peripheral Blood Mononuclear Cells (PBMCs) and Plasma 
Pediatric blood samples were sent to the CVR twice daily from different recruitment sites 
in Pittsburgh for processing.  Blood draws from pediatric patients in the study were conducted 
during normal business hours Monday through Friday.  Samples were delivered to the CVR in 
the morning (twelve o’clock pm) and afternoon (5 o’clock pm) from August 2014 through 
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January 2015.  Each blood tube was checked and documented for time of draw (to ensure the 
draw had occurred within the last four hours), blood draw time point (day 0, 7, or 21), and 
participant identification number.  If a sample had been drawn from a patient more than four 
hours prior to processing, centrifugation time of the sample was be increased.  After verification 
of the blood sample information, cryo tubes for serum, plasma, and PBMC were labeled with the 
following: study name (Pitt Option C), participant ID number, blood draw time point, and date.   
In order to ensure the highest level of purity and viability, the CVR followed the standard 
operating procedure approved by the CDC for all processed blood samples.  PBMC and plasma 
were isolated from whole blood by density gradient centrifugation.  To start, the blood samples 
were received in BD Vacutainer CPT Tubes; these tubes were balanced and centrifuged at 
1600xg for 20 minutes with no brake.  After centrifugation four layers could be recognized: 
plasma, PBMC, a gel barrier, and erythrocytes and neutrophils (Figure 4).  Three 1mL aliquots 
of the top plasma layer were pipetted into three labeled cryo tubes.  Any extra plasma was 
pipetted out and discarded into waste consisting of a 50% bleach solution.  The cryo tubes 
containing plasma where then placed in the -80°C freezer for storage.  
 The PBMC layer was carefully pipetted out and place into a 50 mL conical tube.  The 
conical tubes were then brought to total volume with sterile PBS and centrifuged at 500xg for 15 
mins at room temperature.  Following certification, the supernatant was discarded and the cell 
pellet was resuspended with 1 mL PBS.  Once the pellet was resuspended, PBS was added to 
bring the volume of the conical tube up to 50 mL, and the sample was centrifuged again for 15 
mins at 500xg.  This wash process was repeated two more times.  After the third centrifugation, 
the pellet was resuspended in 10 mL of PBS and 20 µl were used for cell counting.  The conical 
tube was brought to a total volume of 50 mLs with PBS and centrifuged for the last time. 
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While the sample was in the centrifuge, the 20µl cell sample was counted using a 
hemocytometer.  The 20µl sample was mixed with 0.4% trypan blue solution to make a 1:2 
dilution.  The cells were then counted using as hemocytometer; all four outer quadrants were 
counted, the average of the four quadrants was recorded, and that final number represented the 
number of cells (N) x 104/ml in the sample.  This number (N x 104/ml) was multiplied by the 
dilution of trypan blue used (2) and the total volume of cells (10 mL) to obtain the total number 
of recovered PBMCs.  This final number was used to calculate the number of aliquots to be 
frozen, which would contain between 0.5-1.0 x 107 cells/ml.  After the final centrifugation, the 
supernatant was removed and the PBMCs were resuspended in freezing media (90% FBS/10% 
DMSO).   Aliquots of 1 mL were pipetted into labeled cryovials (approx. 1-3 per participant per 
time point) and placed into a Mr. Frosty freezing chamber in a -80°C freezer for slow freezing. 
Cells were keep in the -80°C freezer for no more than 72 hours, at which time they were 
transferred to a liquid nitrogen tank for long-term storage.  Once all the pediatric blood samples 
were processed for plasma and PBMC they were catalogued, organized numerically by 
participant according to the time points, and sent to the CDC or a reference lab for analysis.  
Figure 4. CPT tube separation[18]. 
 Four layers recognized after centrifugation: plasma, PBMC, a gel barrier, and erythrocytes and neutrophils 
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3.3.2 Serum 
An individual blood tube was collected in BD Vacutainer ™ Venous Blood Collection 
Tubes: Serum Separator Tubes on D0 and D21 for the sole purpose of isolating serum.  These 
tubes had a polymer gel layer to separate serum from red blood cells. Serum samples were also 
isolated by centrifugation.  The serum tubes were centrifuged at 1800rpm for 10 minutes.  The 
top serum layer was removed and aliquoted (500µl each) into four labeled cryovial tubes.  Serum 
aliquots were then placed in the -80°C freezer for storage.  Once all the pediatric serum samples 
were processed, they were catalogued, organized numerically by participant according to the 
time points, and sent to the CDC or a reference lab for analysis.  
3.4 ANALYSIS 
3.4.1 Hemagglutination Antibody Inhibition (HAI) Assay 
Processed sera were sent to a CDC contracting lab, Battelle, Inc., where they were 
analyzed using HAI assays.  This assay measures the binding ability of surface protein HA on 
influenza virus to the sialic acid receptors on red blood cells.  If an antibody binds to the HA on 
the influenza virus, then binding of HA to the sialic acid receptors is blocked, and 
hemagglutination occurs.  The assay was performed using day 0 and day 21 sera samples, with 
erythrocytes from poultry (chicken or turkey).   
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A round-bottomed 96-well plate was prepared by pipetting 50 µl of PBS to each well 
rows B-H; Row A had 100µl of virus. 50ul aliquots of virus were added to columns B through H. 
A 2-fold serial dilution by transferring 50µl of solution from column A to B, changing tips, 
mixing then removing 50 µl from B and transferring to C, etc. down the plat to column H.  To 
keep total volume the same amongst wells, 50µl was discarded from row H.  The 96-well plate 
was then incubated for 30 minutes at room temperature.  A 0.5% Turkey red blood cell (TRBC) 
solution (50 µl) was added into all wells and the plate was incubated for another 30 minutes. 
Following incubation, the wells were observed for the appearance of red dots (hemagglutination 
inhibition) or a diffused reddish color (hemagglutination).  Hemagglutination inhibition occurred 
if antibodies were present in the serum samples. A diffused reddish color indicated that 
antibodies were not present and hemagglutination was able to occur.  According to the CDC, 
HAI assay data can be used as a correlate of protection, but this does not necessarily mean a 
person will be protected from influenza infection. 
3.4.2 Microneutralization (MN) Assay 
Serum samples were also sent to the CDC for analysis by MN assays.  This assay was 
used to measure the breadth of antibody response elicited by influenza vaccination and measured 
antibody neutralization to virus strains in the vaccines. The neutralization assay measures two-
fold dilutions of heat-inactivated serum incubated with virus prior to infection of a cell line.   
For this assay, Serum was heat inactivated at 56°C for 30 minutes. A sterile 96 well 
dilution plate was used for the dilution of sera and incubation of sera + virus.  A representation 
of the sera-virus dilution plate can be seen in Figure 3.  For the sera dilutions, 50µl diluent 
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(media) was added to each well rows B-H; Row A had 90µl. 10ul aliquots of sera were added to 
columns 1 through 11, row A; Column 12 wells were used as virus and cell controls for the study 
(Figure 3). A 2-fold serial dilution by transferring 50µl of solution from column A to B, 
changing tips, mixing then removing 50 µl from B and transferring to C, etc. down the plat to 
column H.  To keep total volume the same amongst wells, 50µl was discarded from row H.   
 
 
Figure 5. Virus microneutralization assay plate set up. 
Heat-inactive serum was added to the top row of a 96 well plate (A1-A11) and A 2-fold serial dilution of the serum 
was then conducted (i.e. A1toB1; B1 to B2; etc. down to G1 to H1) 
 
Virus (50 µl) was then added to row A (wells 1-11).  Column 12 was reserved for 
controls and the same controls were used for each plate in the assay.  After the serum dilutions 
were completed, 50µl diluted virus (at TCID50 to achieve MOI = 0.1) was then added to control 
wells.  Serum-virus mixtures were incubated for 1h at 37C.   
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For these assays, we utilized a special cell line, Madin-Darby Canine Kidney-Sialic acid 
over expression (MDCK-SIAT1) cells because some of the virus strains required increased levels 
of sialic acid receptors for the ability to infect in vitro. These cells (100µl) were added to each 
well of the plate and the plate was incubated for 18-20 hours at 37 °C. The titers for the assay 
were the reciprocal of the highest dilution of serum that yielded 50%.   
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4.0  RESULTS 
4.1 AIM: TO COMPARE ANTIBODY RESPONSES ELICITED BY LAIV AND IIV 
VACCINATION IN PEDIATRIC PAITIENTS, AGES 3-17 YEARS OLD. 
4.1.1 HAI Assay Results 
HAI data was analyzed for antibodies to vaccine virus strains: influenza A viruses 
(A/California/7/2009 (H1N1) and A/Texas/50/2012 (H3N2)) and influenza B viruses 
(B/Brisbane and B/Massachusetts).  Titer levels were measured for D0 and D21 from processed 
serum samples. Below are tables displaying the results of the HAI assay conducted (Tables 2-5). 
For this study, the titers were defined as the reciprocal of the last dilution of serum that 
completely inhibited hemagglutination.  
An increase in titer of 4-fold or higher between D0 and D21 sera was considered to be a 
seroconversion; smaller increases in antibody response were not considered to achieve a level 
consistent with seroconversion in the assay.  Further, a reciprocal titer of 80 was considered to be 
non-reactive as this was at or below the cutoff for the assay. Patients that demonstrated positive 
antibody responses at D0 but failed to achieve the 4-fold increase in response at D21 were 
considered to be seroprevalent.  
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     The 3-8 year old cohort receiving the IIV vaccine demonstrated an increased antibody 
response in fifteen out of the twenty participants, seroconverting to one or more of the virus 
strains measured in the assay (Table 2).  Interestingly, two of the patients seroconverted to all 
four virus strains tested. Fourteen of the twenty patients were seroprevalent, demonstrating a 
wide range of reactivity at D0, but not showing a 4-fold increase in antibody titer at D21.  None 
of the pediatric participants that received IIV were non-reactive, with all patients demonstrating 
antibody responses to at least one or more influenza strains tested. 
 
Table 2. Hemagglutination inhibition (HAI) assay data for the 3-8 year old cohort vaccinated with IIV. 
AGE 
GROUP 
2014-15 
Vaccine
DAY 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold
3-8 yo IIV 5 20 4.0 5 20 4.0 40 80 2.0 80 160 2.0
3-8 yo IIV 80 80 1.0 20 160 8.0 10 453 45.3 160 640 4.0
3-8 yo IIV 113 160 1.4 453 640 1.4 57 80 1.4 40 80 2.0
3-8 yo IIV 40 160 4.0 1280 1810 1.4 40 320 8.0 160 320 2.0
3-8 yo IIV 40 160 4.0 80 226 2.8 80 320 4.0 80 160 2.0
3-8 yo IIV 320 320 1.0 5 40 8.0 14 160 11.3 40 320 8.0
3-8 yo IIV 10 320 32.0 20 160 8.0 160 160 1.0 80 226 2.8
3-8 yo IIV 10 453 45.3 5 640 128.0 5 10 2.0 5 113 22.6
3-8 yo IIV 80 640 8.0 80 640 8.0 5 57 11.3 28 640 22.6
3-8 yo IIV 453 640 1.4 113 320 2.8 10 40 4.0 57 160 2.8
3-8 yo IIV 640 640 1.0 80 160 2.0 160 320 2.0 80 320 4.0
3-8 yo IIV 320 640 2.0 80 226 2.8 10 160 16.0 160 453 2.8
3-8 yo IIV 160 640 4.0 5 40 8.0 5 80 16.0 160 640 4.0
3-8 yo IIV 80 640 8.0 5 80 16.0 160 320 2.0 320 640 2.0
3-8 yo IIV 20 640 32.0 10 2560 256.0 5 40 8.0 10 320 32.0
3-8 yo IIV 320 640 2.0 226 640 2.8 14 80 5.7 226 640 2.8
3-8 yo IIV 160 640 4.0 160 640 4.0 57 640 11.3 80 640 8.0
3-8 yo IIV 640 905 1.4 320 640 2.0 226 640 2.8 320 640 2.0
3-8 yo IIV 320 1280 4.0 160 320 2.0 80 640 8.0 640 2560 4.0
3-8 yo IIV 40 2560 64.0 10 160 16.0 80 320 4.0 80 320 4.0
3-8 yo IIV 92 408 4.4 44 264 6.1 30 155 5.2 84 361 4.3
H3N2 H1N1 B/Brisbane B/Massachusetts
The virus used in the assay is listed across the top row.  Reciprocal endpoint antibody titers for D0 (pre-
vaccination) D21 and the fold change between the two time points are listed for each virus strain.  The bottom row 
represents the average for each column (highlighted in red numbers).  Seroconverters (green) are defined as those 
vaccines with at least a 4-fold increase in antibody titer from day 0 to day 21; seroprevalent (yellow) patients are 
defined as those vaccines with positive antibody titers at day 0 and less than 4-fold increase in titer at day 21; non-
reactors are defined as those vaccines whose antibody titers were below the cutoff of the assay (< 1:80) 
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AGE 
GROUP 
2014-15 
Vaccine
DAY 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold
3-8 yo LAIV 20 20 1.0 80 113 1.4 40 57 1.4 40 40 1.0
3-8 yo LAIV 10 20 2.0 5 5 1.0 5 40 8.0 57 320 5.7
3-8 yo LAIV 28 40 1.4 80 80 1.0 10 20 2.0 20 40 2.0
3-8 yo LAIV 40 40 1.0 320 320 1.0 320 320 1.0 226 320 1.4
3-8 yo LAIV 40 57 1.4 20 20 1.0 5 40 8.0 40 80 2.0
3-8 yo LAIV 160 160 1.0 80 80 1.0 160 160 1.0 160 160 1.0
3-8 yo LAIV 160 160 1.0 40 40 1.0 10 20 2.0 10 40 4.0
3-8 yo LAIV 160 160 1.0 5 5 1.0 40 40 1.0 160 160 1.0
3-8 yo LAIV 320 320 1.0 160 160 1.0 160 160 1.0 160 160 1.0
3-8 yo LAIV 320 320 1.0 40 40 1.0 80 160 2.0 160 160 1.0
3-8 yo LAIV 320 320 1.0 40 40 1.0 80 80 1.0 320 320 1.0
3-8 yo LAIV 320 320 1.0 160 226 1.4 320 226 0.7 160 226 1.4
3-8 yo LAIV 57 40 0.7 5 5 1.0 5 5 1.0 40 40 1.0
3-8 yo LAIV 40 40 1.0 80 80 1.0 10 20 2.0 40 80 2.0
3-8 yo LAIV 40 40 1.0 28 20 0.7 40 40 1.0 28 28 1.0
3-8 yo LAIV 80 80 1.0 320 320 1.0 160 160 1.0 7 20 2.8
3-8 yo LAIV 160 80 0.5 40 40 1.0 10 28 2.8 40 80 2.0
3-8 yo LAIV 113 113 1.0 57 40 0.7 80 80 1.0 28 80 2.8
3-8 yo LAIV 160 160 1.0 80 80 1.0 40 80 2.0 40 113 2.8
3-8 yo LAIV 160 160 1.0 160 160 1.0 160 160 1.0 57 160 2.8
3-8 yo LAIV 160 160 1.0 40 40 1.0 80 80 1.0 80 80 1.0
3-8 yo LAIV 320 320 1.0 320 320 1.0 640 640 1.0 320 320 1.0
3-8 yo LAIV 5 5 1.0 5 5 1.0 5 5 1.0 5 40 8.0
3-8 yo LAIV 20 20 1.0 40 40 1.0 40 160 4.0 5 80 16.0
3-8 yo LAIV 10 20 2.0 20 20 1.0 5 160 32.0 5 40 8.0
3-8 yo LAIV 20 28 1.4 80 80 1.0 5 80 16.0 40 113 2.8
3-8 yo LAIV 40 40 1.0 10 20 2.0 20 14 0.7 80 80 1.0
3-8 yo LAIV 40 40 1.0 160 80 0.5 57 40 0.7 10 10 1.0
3-8 yo LAIV 40 80 2.0 7 40 5.7 113 113 1.0 320 80 0.3
3-8 yo LAIV 160 160 1.0 80 80 1.0 160 160 1.0 320 320 1.0
3-8 yo LAIV 160 160 1.0 14 20 1.4 160 160 1.0 7 14 2.0
3-8 yo LAIV 160 160 1.0 160 160 1.0 80 80 1.0 113 160 1.4
3-8 yo LAIV 320 160 0.5 320 320 1.0 10 113 11.3 453 640 1.4
3-8 yo LAIV 320 320 1.0 80 80 1.0 160 160 1.0 160 160 1.0
3-8 yo LAIV 320 320 1.0 320 320 1.0 40 40 1.0 80 320 4.0
3-8 yo LAIV 320 320 1.0 20 20 1.0 80 320 4.0 20 113 5.7
3-8 yo LAIV 320 320 1.0 160 160 1.0 20 40 2.0 5 20 4.0
3-8 yo LAIV 1280 640 0.5 20 20 1.0 5 113 22.6 5 640 128.0
3-8 yo LAIV 640 905 1.4 226 160 0.7 10 160 16.0 5 113 22.6
3-8 yo LAIV 100 103 1 53 55 1 38 74 2 44 98 2
B/MassachusettsB/BrisbaneH1N1H3N2 
In contrast, 3-8 year old patients receiving the LAIV vaccine demonstrated very few 
seroconversions (shown in Table 3).  Only 7 of the 40 vaccines had a 4-fold increase or higher 
antibody response, while 8 of the 40 vaccines were nonreactive. The majority of patients (26 of 
the 40) were seroprevalent, together, this data showed a poor antibody response to the LAIV 
vaccine compared to the IIV vaccine in the 3-8 year old cohort  
 
Table 3. Hemagglutination inhibition (HAI) assays data for the 3-8 year old cohort administered LAIV.  
The virus used in the assay is listed across the top.  Reciprocal endpoint antibody titers for D0 (pre-vaccination) D21 
and the fold change between the two time points are listed for each virus strain.  The bottom row represents the 
average for each column (highlighted in red numbers).  Seroconverters (green) are defined as those vaccines with at 
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least a 4-fold increase in antibody titer from day 0 to day 21; seroprevalent (yellow) patients are defined as those 
vaccines with positive antibody titers at day 0 and less than 4-fold increase in titer at day 21; non-reactors are 
defined as those vaccines whose antibody titers were below the cutoff of the assay (< 1:80) 
 
Next we evaluated the 9-17 year old cohort that received the IIV vaccine.  The results in 
the older children were similar to those observed in the younger children (Table 4).  In general, 
children in the 9-17 year old cohort who received the IIV vaccine had a good antibody response 
to at least one of the four strains of virus in the vaccine.  Out of the 43 participants who received 
IIV, there were 16 seroconverters participants, 39 seroprevalent and 17 non-reactive patients 
across one or more virus strain.  
 
Table 4. Hemagglutination inhibition (HAI) assays data for the 9-17 year old cohort vaccinated with IIV.  
AGE 
GROUP 
2014-15 
Vaccine DAY 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold
9-17 y IIV 80 80 1.0 160 320 2.0 113 160 1.4 40 113 2.8
9-17 y IIV 20 80 4.0 80 160 2.0 20 160 8.0 80 160 2.0
9-17 y IIV 28 80 2.8 20 80 4.0 10 40 4.0 20 320 16.0
9-17 y IIV 80 113 1.4 40 160 4.0 40 113 2.8 80 160 2.0
9-17 y IIV 80 160 2.0 160 160 1.0 80 320 4.0 80 320 4.0
9-17 y IIV 80 160 2.0 40 160 4.0 40 113 2.8 20 40 2.0
9-17 y IIV 80 160 2.0 160 320 2.0 20 80 4.0 160 320 2.0
9-17 y IIV 40 160 4.0 80 160 2.0 40 160 4.0 80 160 2.0
9-17 y IIV 80 160 2.0 20 113 5.7 10 453 45.3 80 226 2.8
9-17 y IIV 160 226 1.4 80 80 1.0 80 80 1.0 80 80 1.0
9-17 y IIV 80 226 2.8 160 640 4.0 80 160 2.0 80 160 2.0
9-17 y IIV 160 320 2.0 320 320 1.0 113 160 1.4 57 80 1.4
9-17 y IIV 160 320 2.0 160 640 4.0 226 453 2.0 80 320 4.0
9-17 y IIV 320 320 1.0 80 113 1.4 14 40 2.8 160 160 1.0
9-17 y IIV 320 320 1.0 226 160 0.7 57 160 2.8 640 640 1.0
9-17 y IIV 80 320 4.0 160 320 2.0 40 80 2.0 320 320 1.0
9-17 y IIV 320 320 1.0 20 113 5.7 80 160 2.0 80 113 1.4
9-17 y IIV 320 320 1.0 57 80 1.4 5 40 8.0 320 640 2.0
9-17 y IIV 160 320 2.0 160 320 2.0 10 80 8.0 160 640 4.0
9-17 y IIV 320 320 1.0 160 320 2.0 80 160 2.0 320 320 1.0
9-17 y IIV 320 320 1.0 160 226 1.4 80 80 1.0 160 160 1.0
9-17 y IIV 320 453 1.4 57 113 2.0 160 160 1.0 640 1280 2.0
9-17 y IIV 320 640 2.0 160 160 1.0 80 80 1.0 160 226 1.4
9-17 y IIV 640 640 1.0 160 160 1.0 80 80 1.0 226 320 1.4
9-17 y IIV 640 640 1.0 160 160 1.0 160 160 1.0 640 640 1.0
9-17 y IIV 640 905 1.4 226 320 1.4 20 640 32.0 640 1280 2.0
9-17 y IIV 320 640 2.0 160 640 4.0 160 320 2.0 160 320 2.0
9-17 y IIV 40 113 2.8 160 640 4.0 10 40 4.0 28 226 8.0
9-17 y IIV 80 160 2.0 10 2560 256.0 40 320 8.0 10 640 64.0
9-17 y IIV 160 320 2.0 320 320 1.0 20 320 16.0 28 320 11.3
9-17 y IIV 40 320 8.0 160 320 2.0 7 160 22.6 113 320 2.8
9-17 y IIV 80 640 8.0 80 160 2.0 20 160 8.0 80 1280 16.0
9-17 y IIV 80 640 8.0 160 640 4.0 80 640 8.0 57 160 2.8
9-17 y IIV 137 271 2 101 236 2 41 144 4 107 273 3
H3N2 H1N1 B/Brisbane B/Massachusetts
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The virus used in the assay is listed across the top.  Reciprocal endpoint antibody titers for D0 (pre-vaccination) D21 
and the fold change between the two time points are listed for each virus strain.  The bottom row represents the 
average for each column (highlighted in red numbers).  Seroconverters (green) are defined as those vaccines with at 
least a 4-fold increase in antibody titer from day 0 to day 21; seroprevalent (yellow) patients are defined as those 
vaccines with positive antibody titers at day 0 and less than 4-fold increase in titer at day 21; non-reactors are 
defined as those vaccines whose antibody titers were below the cutoff of the assay (< 1:80) 
 
 
The LAIV vaccine also failed to elicit a good antibody response in the 9-17 year old 
cohort receiving LAIV.  The majority of children receiving LAIV (45 out of 57) were 
seroprevalent, 7 out of 57 seroconverted to one of the viruses, and 9 out of 57 patients were non-
reactive. As displayed in Table 6, average fold change in antibody response was poor. The 3-8 
year old cohort were seroprevalent for the influenza B virus only where the 9-17 are were non-
reactive across all strains.  
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AGE 
GROUP 
2014-15 
Vaccine DAY 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold
9-17 y LAIV 20 40 2.0 160 160 1.0 57 80 1.4 160 160 1.0
9-17 y LAIV 80 80 1.0 160 160 1.0 20 28 1.4 320 453 1.4
9-17 y LAIV 80 80 1.0 160 160 1.0 20 40 2.0 160 320 2.0
9-17 y LAIV 80 80 1.0 160 160 1.0 80 80 1.0 160 160 1.0
9-17 y LAIV 160 160 1.0 160 160 1.0 40 40 1.0 40 40 1.0
9-17 y LAIV 160 160 1.0 320 320 1.0 160 160 1.0 226 226 1.0
9-17 y LAIV 160 160 1.0 320 226 0.7 80 80 1.0 1280 640 0.5
9-17 y LAIV 226 226 1.0 5 5 1.0 10 10 1.0 14 20 1.4
9-17 y LAIV 80 320 4.0 40 28 0.7 10 160 16.0 226 320 1.4
9-17 y LAIV 160 320 2.0 80 80 1.0 20 20 1.0 640 640 1.0
9-17 y LAIV 320 320 1.0 5 5 1.0 20 20 1.0 160 160 1.0
9-17 y LAIV 320 320 1.0 226 160 0.7 160 160 1.0 226 160 0.7
9-17 y LAIV 320 320 1.0 7 5 0.7 40 40 1.0 113 80 0.7
9-17 y LAIV 226 320 1.4 5 10 2.0 14 14 1.0 160 320 2.0
9-17 y LAIV 320 320 1.0 160 160 1.0 40 80 2.0 80 320 4.0
9-17 y LAIV 320 320 1.0 160 160 1.0 28 40 1.4 320 80 0.3
9-17 y LAIV 320 320 1.0 320 320 1.0 40 40 1.0 40 160 4.0
9-17 y LAIV 320 320 1.0 160 160 1.0 80 80 1.0 20 40 2.0
9-17 y LAIV 640 453 0.7 80 80 1.0 80 80 1.0 160 160 1.0
9-17 y LAIV 640 640 1.0 160 160 1.0 20 20 1.0 160 160 1.0
9-17 y LAIV 20 20 1.0 80 80 1.0 40 40 1.0 113 80 0.7
9-17 y LAIV 40 40 1.0 5 5 1.0 10 20 2.0 20 28 1.4
9-17 y LAIV 40 40 1.0 10 10 1.0 20 20 1.0 160 226 1.4
9-17 y LAIV 57 57 1.0 20 20 1.0 5 5 1.0 80 80 1.0
9-17 y LAIV 160 160 1.0 160 80 0.5 80 80 1.0 160 113 0.7
9-17 y LAIV 320 160 0.5 5 5 1.0 40 40 1.0 57 57 1.0
9-17 y LAIV 160 160 1.0 226 320 1.4 40 40 1.0 40 40 1.0
9-17 y LAIV 160 160 1.0 40 40 1.0 10 14 1.4 160 160 1.0
9-17 y LAIV 320 226 0.7 320 320 1.0 320 226 0.7 640 640 1.0
9-17 y LAIV 453 453 1.0 160 160 1.0 40 80 2.0 40 80 2.0
9-17 y LAIV 320 640 2.0 20 40 2.0 160 320 2.0 160 320 2.0
9-17 y LAIV 160 640 4.0 80 80 1.0 40 57 1.4 57 57 1.0
9-17 y LAIV 320 2560 8.0 80 160 2.0 57 80 1.4 226 320 1.4
9-17 y LAIV 28 14 0.5 80 113 1.4 80 80 1.0 320 320 1.0
9-17 y LAIV 10 14 1.4 14 20 1.4 80 80 1.0 160 160 1.0
9-17 y LAIV 20 20 1.0 80 80 1.0 160 160 1.0 320 320 1.0
9-17 y LAIV 20 20 1.0 57 40 0.7 20 20 1.0 40 57 1.4
9-17 y LAIV 20 20 1.0 5 10 2.0 5 10 2.0 28 40 1.4
9-17 y LAIV 40 40 1.0 10 20 2.0 5 10 2.0 5 10 2.0
9-17 y LAIV 40 40 1.0 20 20 1.0 5 5 1.0 5 5 1.0
9-17 y LAIV 40 40 1.0 640 640 1.0 20 20 1.0 226 226 1.0
9-17 y LAIV 40 57 1.4 40 160 4.0 80 80 1.0 40 40 1.0
9-17 y LAIV 113 113 1.0 20 20 1.0 5 5 1.0 5 10 2.0
9-17 y LAIV 160 160 1.0 20 20 1.0 20 40 2.0 10 40 4.0
9-17 y LAIV 160 160 1.0 80 80 1.0 80 80 1.0 160 160 1.0
9-17 y LAIV 160 160 1.0 320 320 1.0 160 113 0.7 20 20 1.0
9-17 y LAIV 160 160 1.0 40 40 1.0 20 40 2.0 40 80 2.0
9-17 y LAIV 80 160 2.0 10 20 2.0 5 57 11.3 5 40 8.0
9-17 y LAIV 160 160 1.0 5 20 4.0 10 80 8.0 20 160 8.0
9-17 y LAIV 320 320 1.0 80 80 1.0 5 10 2.0 5 10 2.0
9-17 y LAIV 320 320 1.0 80 80 1.0 40 40 1.0 10 57 5.7
9-17 y LAIV 320 320 1.0 7 7 1.0 20 20 1.0 20 20 1.0
9-17 y LAIV 320 320 1.0 453 453 1.0 40 80 2.0 10 320 32.0
9-17 y LAIV 320 320 1.0 80 80 1.0 160 160 1.0 160 160 1.0
9-17 y LAIV 453 453 1.0 80 80 1.0 80 80 1.0 320 320 1.0
9-17 y LAIV 130 146 1 54 59 1 32 43 1 72 102 1
H3 H1 B/Brisbane B/Massachusetts
Table 5. Hemagglutination inhibition (HAI) assays for the 9-17 year old cohort vaccinated with LAIV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The virus used in the assay is listed across the top.  Reciprocal endpoint antibody titers for D0 (pre-vaccination) D21 
and the fold change between the two time points are listed for each virus strain.  The bottom row represents the 
average for each column (highlighted in red numbers).  Seroconverters (green) are defined as those vaccines with at 
least a 4-fold increase in antibody titer from day 0 to day 21; seroprevalent (yellow) patients are defined as those 
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vaccines with positive antibody titers at day 0 and less than 4-fold increase in titer at day 21; non-reactors are 
defined as those vaccines whose antibody titers were below the cutoff of the assay (< 1:80) 
 
 
 
Overall, the 3-8 year old cohort vaccinated with IIV, had the best antibody response.  
Average fold increase for this cohort was 4-fold or higher across all four strains (Table 6). The 9-
17 year old cohort vaccinated with IIV had an average 4-fold or higher increase in the influenza 
B virus (B/Brisbane) while all responses to all other strains were less than 4-fold (table 6).  For 
the cohorts who received LAIV, the 3-8 year olds on average demonstrated seroprevalance to 
both influenza B viruses only; average antibody reactivity to influenza A viruses in the 3-8 year 
old group and all viruses tested in the 9-17 year old group was non-reactive. 
 
Table 6. Average fold change in HAI titers demonstrated more robust antibody responses in younger children 
(3-8 yr cohort) receiving IIV vaccination.  
 2014-15 
vaccine 
A/H3N2 
Avg. Fold 
A/H1N1 
Avg. Fold 
B/Brisbane 
Avg. Fold 
B/Mass 
Avg. Fold 
3-8 yr 
 
LAIV 1 1 2 2 
IIV 4.4 6.1 5.2 4.3 
9-17 yr  LAIV 1 1 1 1 
IIV 2 2 4 3 
Seroconverters (green) are defined as those vaccines with at least a 4-fold increase in antibody titer from day 0 to 
day 21; seroprevalent (yellow) patients are defined as those vaccines with positive antibody titers at day 0 and less 
than 4-fold increase in titer at day 21; non-reactors (no shading) are defined as those vaccines whose antibody titers 
were below the cutoff of the assay and/or whose change from D0 to D21 was ≤1. 
 
4.1.2 HAI Assay Statistics 
Statistical analysis of the HAI data was conducted using a paired, two tailed t-test.  We 
reviewed the P values for the 3-8 year old and 9-17 year old cohort antibody levels, comparing 
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day 0 to day 21, across all virus strains. Those vaccinated with IIV demonstrated a significant 
increase in antibody response across all strains, for both cohorts, had (Table 7).  In contrast, 
neither the 3-8 year old nor 9-17 year old cohort vaccinated with LAIV had a significant increase 
in HAI antibody titer to the influenza A viruses (H3N2 & H1N1); interestingly, significant HAI 
antibody titers to the influenza B viruses (B/Brisbane & B/Massachusetts) were observed for 
both cohorts.  Thus, the data demonstrated that, using a paired t test to directly compare the D0 
and D21 antibody titers, the IIV vaccine was capable of eliciting a significant antibody response 
to all vaccine strains in all vaccine recipients in an age-independent manner.  In contrast, the 
LAIV vaccine only elicited significant antibody responses to the B virus strains, but this 
antibody response was also in an age-independent manner. 
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Table 7. Significant Antibody responses elicited by IIV demonstrated increased breadth to all vaccine strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aVirus Strain tested in HAI assay 
bVaccine received 
cAge Group of cohort 
dMean of Difference in HAI Titer D21-D0 
eDegrees of Freedom 
fP value as determined by paired, two-tailed, t test 
gNumber of D0D21 pairs analyzed 
 
 
 
Virus straina Vaccineb Age 
Groupc 
Mean of 
diffd 
Degrees of 
freedome 
P valuef # of 
pairsg 
H3N2 
 LAIV 3-8 -13.72 38 0.4629 39 
9-17 58.18 54 0.1754  
IIV 3-8 416.4 19 0.0035 20 
9-17 129.3 32 0.0001 33 
H1N1 
 LAIV 3-8 -0.5897 38 0.8657 39 
9-17 2.309 54 0.5810 55 
IIV 3-8 350.3 19 0.0104 20 
9-17 207.3 32 0.0125 33 
B/Brisbane 
 LAIV 3-8 28.44 38 0.0051 39 
9-17 10.6 54 0.0314 55 
IIV 3-8 185.1 19 0.0002 20 
9-17 129 32 0.0001 33 
B/Massachusetts 
 LAIV 3-8 54.97 38 0.0084 39 
9-17 16.15 54 0.3218 55 
IIV 3-8 359.3 19 0.0008 20 
9-17 199.5 32 0.0001 33 
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4.1.3 MN Assay Results 
Influenza A (H3N2) virus was the predominant virus in circulation for the 2014-2015 
season [19]. Therefore, to evaluate the functional relevance (i.e., ability of antibody to neutralize 
influenza replication) and the breadth of antibody elicited by vaccination to the circulating 
strains, we analyzed the MN titer levels using day 0 and day 21 serum samples, testing against 
three A (H3N2) viruses: A/ Texas/50/2012 (vaccine-matched strain), 
A/Switzerland/9715293/2013 and A/Nebraska/04/2014 (variant circulating strains) [20]. The 
data and vaccine groups were further stratified by the vaccine administered in the prior year. 
Geometric mean titers in 3-8 year olds vaccinated with IIV demonstrated increases to all 
three H3N2 strains tested.  In contrast, children in the 3-8 year old cohort vaccinated with LAIV 
in 2014-15 failed to demonstrate increased in GMT at D21 compared to D0 to any H3 strain 
tested (Figure 6).  When looking at the contribution of 2013-14 vaccination history on the 2014-
15 MN antibody response, no conclusive correlation was possible, since only the patients 
receiving IIV in 2014-15 also received IIV in 2013-14.  However, data suggests that the IIV 
vaccine was better at priming and boosting the MN antibody response (Figure 6).  Further 
analyses will be necessary to tease this apart.   
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Figure 6. Geometric Mean titers demonstrated broad neutralization against vaccine and variant H3N2 virus 
strains in 3-8 year olds vaccinated with IIV  [20]. 
 
Reciprocal Log 2 geometric mean antibody titers (GMT) as measured by microneutralization assay to the vaccine 
(H3N2 (A/ Texas/50/2012) and variant (A/Switzerland/9715293/2013 and A/Nebraska/04/2014) H3N2 virus strains 
on day 0 (pre vaccination) and day 21; the x-axis lists both the 2014-15 vaccine as well as the reported 2013-14 
vaccine type administered to the 3-8 year old cohort.  
 
 
Similar to data observed in the 3-8 year old cohort, GMT in 9-17 year olds vaccinated 
with IIV displayed increases to all three H3N2 strains tested.  Similarly, vaccination of the older 
cohort with LAIV in 2014-15 failed to demonstrate appreciable increases in GMT at D21 
compared to D0 to any H3 strain tested.  Interestingly, when looking at the contribution of 2013-
14 vaccination history on the 2014-15 MN antibody response, LAIV vaccination in the prior year  
(2013-14) was associated with higher antibody titers at D21 in 2014-15 IIV vaccine recipients 
compared to those receiving IIV in 2013-14.   While these differences were not significant, the 
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data suggests that LAIV vaccination may serve to prime a better immune memory so that IIV 
vaccination would result in a more robust neutralizing antibody response.   
 
 
 
Figure 7. Geometric Mean titers demonstrated broad neutralization against vaccine and variant H3N2 virus 
strains in 9-17 year olds vaccinated with IIV, with LAIV vaccination in prior year providing better immune 
memory.  [20]. 
 
Reciprocal Log 2 geometric mean antibody titers (GMT) as measured by microneutralization assay to the vaccine 
(H3N2 (A/ Texas/50/2012) and variant (A/Switzerland/9715293/2013 and A/Nebraska/04/2014) H3N2 virus strains 
on day 0 (pre vaccination) and day 21; the x-axis lists both the 2014-15 vaccine as well as the reported 2013-14 
vaccine type administered to the 3-8 year old cohort.  
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5.0    DISCUSSION 
Results from the HAI and MN assays demonstrated that patients in both the younger and 
older cohorts had increased antibody titers (HAI) and increased breadth of neutralization (MN) 
to at least one or more viruses present in the vaccine, in patients immunized with IIV.   In 
contrast, the quadrivalent LAIV vaccine failed to elicit antibody titers above the DO levels in 
either cohort.  At first glance these results seemed to suggest that IIV was superior as a vaccine 
when compared to LAIV.  However there are several important issues that must be addressed 
with these findings. 
One of the items addressed was participant’s vaccination history for the previous 
influenza season (2013-2014). After careful review of this data, it seems that past vaccination 
played at least a partial role in the quantitative level of antibody response elicited by the 
participants in particular age groups. This may be in part due to a booster effect (i.e., generation 
of immune memory) from the previous vaccine. 
 In the 3-8 year old group receiving the IIV vaccine for both the 2013-14 and 2014-15 
seasons, increased HAI titers were observed with the majority of the vaccines being 
seroconverters (Table 9).  When the 3-8 year old group had no vaccination in the prior year, they 
also demonstrated increased seroconversion when vaccinated with LAIV, but only to B strains.   
Vaccination in both years, they also demonstrated increased HAI titers but not to the same 
quantitative level (more seroprevalent/yellow vs. seroconverter/green) (Table 9).  Thus, it 
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appears that IIV vaccination was able to elicit a higher quantitative level of antibodies in younger 
children.  Interestingly, when the 9-17 year old cohort was vaccinated with LAIV in 2013-14, 
they had higher levels of antibodies compared to IIV/IIV recipients.  This suggests that LAIV 
may serve to stimulate better immune memory and warrants further evaluation, as there was no 
comparable group to evaluate in the 3-8 year old cohort.   
 
 
Table 8. Hemagglutination antibody inhibition (HAI) titers show that prior vaccination (2013-14) with IIV 
results in increased seroconversion in 3-8 year olds vaccinated with IIV again in subsequent year (2014-15) 
 
 
 
When looking at quantitate levels of antibody by HAI, it seems that IIV, especially in the 
younger cohort (3-8year olds) being administered consecutively played a role in the overall 
increase (Table 9).  For those administered LAIV consecutively, we observed a poor antibody 
response (Table 8 and 9). This could be due to LAIV vaccine not producing a booster effect like 
IIV seem to elicit or the issues that arose with the LAIV vaccine for the 2014-2015 season (see 
below). 
 
Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold 
3-8 yo IIV IIV 80 80 1.0 20 160 8.0 10 453 45.3 160 640 4.0
3-8 yo IIV IIV 113 160 1.4 453 640 1.4 57 80 1.4 40 80 2.0
3-8 yo IIV IIV 40 160 4.0 1280 1810 1.4 40 320 8.0 160 320 2.0
3-8 yo IIV IIV 40 160 4.0 80 226 2.8 80 320 4.0 80 160 2.0
3-8 yo IIV IIV 320 320 1.0 5 40 8.0 14 160 11.3 40 320 8.0
3-8 yo IIV IIV 10 320 32.0 20 160 8.0 160 160 1.0 80 226 2.8
3-8 yo IIV IIV 10 453 45.3 5 640 128.0 5 10 2.0 5 113 22.6
3-8 yo IIV IIV 80 640 8.0 80 640 8.0 5 57 11.3 28 640 22.6
3-8 yo IIV IIV 453 640 1.4 113 320 2.8 10 40 4.0 57 160 2.8
3-8 yo IIV IIV 640 640 1.0 80 160 2.0 160 320 2.0 80 320 4.0
3-8 yo IIV IIV 320 640 2.0 80 226 2.8 10 160 16.0 160 453 2.8
3-8 yo IIV IIV 160 640 4.0 5 40 8.0 5 80 16.0 160 640 4.0
3-8 yo IIV IIV 80 640 8.0 5 80 16.0 160 320 2.0 320 640 2.0
3-8 yo IIV IIV 20 640 32.0 10 2560 256.0 5 40 8.0 10 320 32.0
3-8 yo IIV IIV 320 640 2.0 226 640 2.8 14 80 5.7 226 640 2.8
3-8 yo IIV IIV 160 640 4.0 160 640 4.0 57 640 11.3 80 640 8.0
3-8 yo IIV IIV 640 905 1.4 320 640 2.0 226 640 2.8 320 640 2.0
3-8 yo IIV IIV 320 1280 4.0 160 320 2.0 80 640 8.0 640 2560 4.0
3-8 yo IIV IIV 40 2560 64.0 10 160 16.0 80 320 4.0 80 320 4.0
3-8 yo IIV IIV 107 478 4.5 44 264 6.1 30 155 5.2 84 361 4.3
B/ MassachusettsAGE 
Group 
2013-14 
vaccine
2014-15 
vaccine
H3N2 H1N1 B/BRISSBANE
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Table 9. Hemagglutination antibody inhibition (HAI) titers show that prior vaccination has no effect on LAIV 
vaccination in 3-8 year olds while no vaccination provide LAIV-induced immune memory against B strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold 
3-8 yo IIV LAIV 10 20 2.0 5 5 1.0 5 40 8.0 57 320 5.7
3-8 yo IIV LAIV 28 40 1.4 80 80 1.0 10 20 2.0 20 40 2.0
3-8 yo IIV LAIV 40 40 1.0 320 320 1.0 320 320 1.0 226 320 1.4
3-8 yo IIV LAIV 40 57 1.4 20 20 1.0 5 40 8.0 40 80 2.0
3-8 yo IIV LAIV 160 160 1.0 80 80 1.0 160 160 1.0 160 160 1.0
3-8 yo IIV LAIV 160 160 1.0 40 40 1.0 10 20 2.0 10 40 4.0
3-8 yo IIV LAIV 160 160 1.0 5 5 1.0 40 40 1.0 160 160 1.0
3-8 yo IIV LAIV 320 320 1.0 160 160 1.0 160 160 1.0 160 160 1.0
3-8 yo IIV LAIV 320 320 1.0 40 40 1.0 80 160 2.0 160 160 1.0
3-8 yo IIV LAIV 320 320 1.0 40 40 1.0 80 80 1.0 320 320 1.0
3-8 yo IIV LAIV 320 320 1.0 160 226 1.4 320 226 0.7 160 226 1.4
3-8 yo IIV LAIV 106 120 1.1 48 50 1.1 45 76 1.7 85 131 1.5
3-8 yo LAIV LAIV 57 40 0.7 5 5 1.0 5 5 1.0 40 40 1.0
3-8 yo LAIV LAIV 40 40 1.0 80 80 1.0 10 20 2.0 40 80 2.0
3-8 yo LAIV LAIV 40 40 1.0 28 20 0.7 40 40 1.0 28 28 1.0
3-8 yo LAIV LAIV 80 80 1.0 320 320 1.0 160 160 1.0 7 20 2.8
3-8 yo LAIV LAIV 160 80 0.5 40 40 1.0 10 28 2.8 40 80 2.0
3-8 yo LAIV LAIV 113 113 1.0 57 40 0.7 80 80 1.0 28 80 2.8
3-8 yo LAIV LAIV 160 160 1.0 80 80 1.0 40 80 2.0 40 113 2.8
3-8 yo LAIV LAIV 160 160 1.0 160 160 1.0 160 160 1.0 57 160 2.8
3-8 yo LAIV LAIV 160 160 1.0 40 40 1.0 80 80 1.0 80 80 1.0
3-8 yo LAIV LAIV 320 320 1.0 320 320 1.0 640 640 1.0 320 320 1.0
3-8 yo LAIV LAIV 106 95 0.9 65 61 0.9 49 63 1.3 43 75 1.7
3-8 yo No vax LAIV 5 5 1.0 5 5 1.0 5 5 1.0 5 40 8.0
3-8 yo No vax LAIV 20 20 1.0 40 40 1.0 40 160 4.0 5 80 16.0
3-8 yo No vax LAIV 10 20 2.0 20 20 1.0 5 160 32.0 5 40 8.0
3-8 yo No vax LAIV 20 28 1.4 80 80 1.0 5 80 16.0 40 113 2.8
3-8 yo No vax LAIV 40 40 1.0 10 20 2.0 20 14 0.7 80 80 1.0
3-8 yo No vax LAIV 40 40 1.0 160 80 0.5 57 40 0.7 10 10 1.0
3-8 yo No vax LAIV 40 80 2.0 7 40 5.7 113 113 1.0 320 80 0.3
3-8 yo No vax LAIV 160 160 1.0 80 80 1.0 160 160 1.0 320 320 1.0
3-8 yo No vax LAIV 160 160 1.0 14 20 1.4 160 160 1.0 7 14 2.0
3-8 yo No vax LAIV 160 160 1.0 160 160 1.0 80 80 1.0 113 160 1.4
3-8 yo No vax LAIV 320 160 0.5 320 320 1.0 10 113 11.3 453 640 1.4
3-8 yo No vax LAIV 320 320 1.0 80 80 1.0 160 160 1.0 160 160 1.0
3-8 yo No vax LAIV 320 320 1.0 320 320 1.0 40 40 1.0 80 320 4.0
3-8 yo No vax LAIV 320 320 1.0 20 20 1.0 80 320 4.0 20 113 5.7
3-8 yo No vax LAIV 320 320 1.0 160 160 1.0 20 40 2.0 5 20 4.0
3-8 yo No vax LAIV 1280 640 0.5 20 20 1.0 5 113 22.6 5 640 128.0
3-8 yo No vax LAIV 640 905 1.4 226 160 0.7 10 160 16.0 5 113 22.6
3-8 yo No vax LAIV 102 106 1.0 50 55 1.1 29 80 2.8 28 94 3.3
AGE 
Group 
2013-14 
vaccine
2014-15 
vaccine
H3N2 H1N1 B/BRISSBANE B/ Massachusetts
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Table 10. Hemagglutination inhibition (HAI) assays data show vaccination in the 2013-2014 and 2014-2015 
vaccine season for the 9-17 year olds.  
 
 
 
 
 
 
 
 
 
 
 
Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold 
9-17 y IIV IIV 20 80 4.0 80 160 2.0 20 160 8.0 80 160 2.0
9-17 y IIV IIV 28 80 2.8 20 80 4.0 10 40 4.0 20 320 16.0
9-17 y IIV IIV 80 113 1.4 40 160 4.0 40 113 2.8 80 160 2.0
9-17 y IIV IIV 80 160 2.0 160 160 1.0 80 320 4.0 80 320 4.0
9-17 y IIV IIV 80 160 2.0 40 160 4.0 40 113 2.8 20 40 2.0
9-17 y IIV IIV 80 160 2.0 160 320 2.0 20 80 4.0 160 320 2.0
9-17 y IIV IIV 40 160 4.0 80 160 2.0 40 160 4.0 80 160 2.0
9-17 y IIV IIV 80 160 2.0 20 113 5.7 10 453 45.3 80 226 2.8
9-17 y IIV IIV 160 226 1.4 80 80 1.0 80 80 1.0 80 80 1.0
9-17 y IIV IIV 80 226 2.8 160 640 4.0 80 160 2.0 80 160 2.0
9-17 y IIV IIV 160 320 2.0 320 320 1.0 113 160 1.4 57 80 1.4
9-17 y IIV IIV 160 320 2.0 160 640 4.0 226 453 2.0 80 320 4.0
9-17 y IIV IIV 320 320 1.0 80 113 1.4 14 40 2.8 160 160 1.0
9-17 y IIV IIV 320 320 1.0 226 160 0.7 57 160 2.8 640 640 1.0
9-17 y IIV IIV 80 320 4.0 160 320 2.0 40 80 2.0 320 320 1.0
9-17 y IIV IIV 320 320 1.0 20 113 5.7 80 160 2.0 80 113 1.4
9-17 y IIV IIV 320 320 1.0 57 80 1.4 5 40 8.0 320 640 2.0
9-17 y IIV IIV 160 320 2.0 160 320 2.0 10 80 8.0 160 640 4.0
9-17 y IIV IIV 320 320 1.0 160 320 2.0 80 160 2.0 320 320 1.0
9-17 y IIV IIV 320 320 1.0 160 226 1.4 80 80 1.0 160 160 1.0
9-17 y IIV IIV 320 453 1.4 57 113 2.0 160 160 1.0 640 1280 2.0
9-17 y IIV IIV 320 640 2.0 160 160 1.0 80 80 1.0 160 226 1.4
9-17 y IIV IIV 640 640 1.0 160 160 1.0 80 80 1.0 226 320 1.4
9-17 y IIV IIV 640 640 1.0 160 160 1.0 160 160 1.0 640 640 1.0
9-17 y IIV IIV 640 905 1.4 226 320 1.4 20 640 32.0 640 1280 2.0
9-17 y IIV IIV 320 640 2.0 160 640 4.0 160 320 2.0 160 320 2.0
9-17 y IIV IIV 162 276 1.7 99 195 2.0 46 133 2.9 140 262 1.9
9-17 y LAIV IIV 40 113 2.8 160 640 4.0 10 40 4.0 28 226 8.0
9-17 y LAIV IIV 80 160 2.0 10 2560 256.0 40 320 8.0 10 640 64.0
9-17 y LAIV IIV 160 320 2.0 320 320 1.0 20 320 16.0 28 320 11.3
9-17 y LAIV IIV 40 320 8.0 160 320 2.0 7 160 22.6 113 320 2.8
9-17 y LAIV IIV 80 640 8.0 80 160 2.0 20 160 8.0 80 1280 16.0
9-17 y LAIV IIV 80 640 8.0 160 640 4.0 80 640 8.0 57 160 2.8
9-17 y LAIV IIV 71 302 4.2 101 508 5.0 21 202 9.5 40 381 9.5
B/ MassachusettsAGE 
Group 
2013-14 
vaccine
2014-15 
vaccine
H3N2 H1N1 B/BRISSBANE
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Table 11. Hemagglutination antibody inhibition (HAI) titers show that no or IIV vaccination in 2013-14 
resulted in increased seroprevalence following LAIV vaccination in 2014-15. 
 
. 
 
 
Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold Day 0 Day 21 Fold 
9-17 y IIV LAIV 80 80 1.0 160 160 1.0 20 28 1.4 320 453 1.4
9-17 y IIV LAIV 80 80 1.0 160 160 1.0 20 40 2.0 160 320 2.0
9-17 y IIV LAIV 80 80 1.0 160 160 1.0 80 80 1.0 160 160 1.0
9-17 y IIV LAIV 160 160 1.0 160 160 1.0 40 40 1.0 40 40 1.0
9-17 y IIV LAIV 160 160 1.0 320 320 1.0 160 160 1.0 226 226 1.0
9-17 y IIV LAIV 160 160 1.0 320 226 0.7 80 80 1.0 1280 640 0.5
9-17 y IIV LAIV 226 226 1.0 5 5 1.0 10 10 1.0 14 20 1.4
9-17 y IIV LAIV 80 320 4.0 40 28 0.7 10 160 16.0 226 320 1.4
9-17 y IIV LAIV 160 320 2.0 80 80 1.0 20 20 1.0 640 640 1.0
9-17 y IIV LAIV 320 320 1.0 5 5 1.0 20 20 1.0 160 160 1.0
9-17 y IIV LAIV 320 320 1.0 226 160 0.7 160 160 1.0 226 160 0.7
9-17 y IIV LAIV 320 320 1.0 7 5 0.7 40 40 1.0 113 80 0.7
9-17 y IIV LAIV 226 320 1.4 5 10 2.0 14 14 1.0 160 320 2.0
9-17 y IIV LAIV 320 320 1.0 160 160 1.0 40 80 2.0 80 320 4.0
9-17 y IIV LAIV 320 320 1.0 160 160 1.0 28 40 1.4 320 80 0.3
9-17 y IIV LAIV 320 320 1.0 320 320 1.0 40 40 1.0 40 160 4.0
9-17 y IIV LAIV 320 320 1.0 160 160 1.0 80 80 1.0 20 40 2.0
9-17 y IIV LAIV 640 453 0.7 80 80 1.0 80 80 1.0 160 160 1.0
9-17 y IIV LAIV 640 640 1.0 160 160 1.0 20 20 1.0 160 160 1.0
9-17 y IIV LAIV 214 190 1.1 77 190 1.0 36 190 1.3 141 190 1.2
9-17 y LAIV LAIV 20 20 1.0 80 80 1.0 40 40 1.0 113 80 0.7
9-17 y LAIV LAIV 40 40 1.0 5 5 1.0 10 20 2.0 20 28 1.4
9-17 y LAIV LAIV 40 40 1.0 10 10 1.0 20 20 1.0 160 226 1.4
9-17 y LAIV LAIV 57 57 1.0 20 20 1.0 5 5 1.0 80 80 1.0
9-17 y LAIV LAIV 160 160 1.0 160 80 0.5 80 80 1.0 160 113 0.7
9-17 y LAIV LAIV 320 160 0.5 5 5 1.0 40 40 1.0 57 57 1.0
9-17 y LAIV LAIV 160 160 1.0 226 320 1.4 40 40 1.0 40 40 1.0
9-17 y LAIV LAIV 160 160 1.0 40 40 1.0 10 14 1.4 160 160 1.0
9-17 y LAIV LAIV 320 226 0.7 320 320 1.0 320 226 0.7 640 640 1.0
9-17 y LAIV LAIV 453 453 1.0 160 160 1.0 40 80 2.0 40 80 2.0
9-17 y LAIV LAIV 320 640 2.0 20 40 2.0 160 320 2.0 160 320 2.0
9-17 y LAIV LAIV 160 640 4.0 80 80 1.0 40 57 1.4 57 57 1.0
9-17 y LAIV LAIV 320 2560 8.0 80 160 2.0 57 80 1.4 226 320 1.4
9-17 y LAIV LAIV 136 173 1.3 46 50 1.1 37 46 1.2 99 113 1.1
9-17 y No vax LAIV 28 14 0.5 80 113 1.4 80 80 1.0 320 320 1.0
9-17 y No vax LAIV 10 14 1.4 14 20 1.4 80 80 1.0 160 160 1.0
9-17 y No vax LAIV 20 20 1.0 80 80 1.0 160 160 1.0 320 320 1.0
9-17 y No vax LAIV 20 20 1.0 57 40 0.7 20 20 1.0 40 57 1.4
9-17 y No vax LAIV 20 20 1.0 5 10 2.0 5 10 2.0 28 40 1.4
9-17 y No vax LAIV 40 40 1.0 10 20 2.0 5 10 2.0 5 10 2.0
9-17 y No vax LAIV 40 40 1.0 20 20 1.0 5 5 1.0 5 5 1.0
9-17 y No vax LAIV 40 40 1.0 640 640 1.0 20 20 1.0 226 226 1.0
9-17 y No vax LAIV 40 57 1.4 40 160 4.0 80 80 1.0 40 40 1.0
9-17 y No vax LAIV 113 113 1.0 20 20 1.0 5 5 1.0 5 10 2.0
9-17 y No vax LAIV 160 160 1.0 20 20 1.0 20 40 2.0 10 40 4.0
9-17 y No vax LAIV 160 160 1.0 80 80 1.0 80 80 1.0 160 160 1.0
9-17 y No vax LAIV 160 160 1.0 320 320 1.0 160 113 0.7 20 20 1.0
9-17 y No vax LAIV 160 160 1.0 40 40 1.0 20 40 2.0 40 80 2.0
9-17 y No vax LAIV 80 160 2.0 10 20 2.0 5 57 11.3 5 40 8.0
9-17 y No vax LAIV 160 160 1.0 5 20 4.0 10 80 8.0 20 160 8.0
9-17 y No vax LAIV 320 320 1.0 80 80 1.0 5 10 2.0 5 10 2.0
9-17 y No vax LAIV 320 320 1.0 80 80 1.0 40 40 1.0 10 57 5.7
9-17 y No vax LAIV 320 320 1.0 7 7 1.0 20 20 1.0 20 20 1.0
9-17 y No vax LAIV 320 320 1.0 453 453 1.0 40 80 2.0 10 320 32.0
9-17 y No vax LAIV 320 320 1.0 80 80 1.0 160 160 1.0 160 160 1.0
9-17 y No vax LAIV 453 453 1.0 80 80 1.0 80 80 1.0 320 320 1.0
9-17 y No vax LAIV 89 92 1.0 41 52 1.3 26 38 1.5 32 61 1.9
AGE 
Group 
2013-14 
vaccine
2014-15 
vaccine
H3N2 H1N1 B/BRISSBANE B/ Massachusetts
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When reviewing this past vaccination history in the MN data we see similar results to that 
of the HAI regarding prior vaccination.  Many of the patients had preexisting neutralizing 
antibodies to A/Texas/50/2012 and many reached post vaccination titers (MN titers ≥40 and 
≥110) against circulating  H3N2 viruses(Figure 8)[20]. Pre- vaccination titers to 
A/Texas/50/2012 (vaccine- matched strain) were a stronger predictor of seroconversion to 
circulating strains, even more so than vaccination history and age of patient. However, it is 
difficult to prove that the higher baseline titers of A/Texas/50/2012(vaccine-matched strain) are 
not directly related to the age of the patient and prior vaccine history[20]. From the MN data we 
can see that those in the 9-17 year old cohort had higher baseline titers then those in the 3-8 year 
old cohort. This would strongly suggest that due to the naivety of the younger 3-8 year old 
cohort’s immune system, they have not yet produced antibodies specific to the virus strains like 
the 9-17 year old cohort, whose past exposure generates a larger antibody repertoire. When 
looking at past vaccination history and its impact on baseline levels, we see there are differences, 
by age cohort and prior vaccination history that contribute to elicitation of higher antibody 
responses to current vaccination vs. higher baseline titers. 
The 3-8 year old cohort, those with a past vaccination of IIV for 2013-14 season and IIV 
for the 2014-2015 season had highest overall antibody responses. The 9-17 year old cohort saw 
highest antibody response with those administered LAIV in the 2013-14 season and IIV for the 
2014-15 season.  This shows that past vaccination history along with age of patient does have 
impact on the antibody response, and may need to be taken into account when developing future 
indicators or predicators of vaccine efficacy. 
Late into the influenza season, it became apparent that two of the strains predicted for 
2014-2015 influenza vaccines [A/Texas/50/2012(H3N2) and B/Massachusetts/2/2012] did not 
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correlate with variant influenza strains circulating in the 2014-2015 season.  Although this 
discrepancy did not affect our study, it did decrease the effectiveness of the vaccine to protect 
from the circulating strains.  Shortly after this information surfaced, MedImmune, the sole 
producer of the LAIV vaccine, released an article addressing a production issue associated with 
the 2014-2015 vaccine. They concluded that the stability of the HA stalk in one of the predicted 
viruses, H1N1, was unstable and demonstrated free HA protein and much precipitated vaccine 
falling out of solution [21]. It was hypothesized that during transportation, the vaccine was 
exposed to high temperatures (>80°F) over an extended period of time; given the temperature 
sensitivity of the virus, this resulted in virus instability and protein precipitation.  Based on this 
issue, MedImmune chose to replace the H1N1 virus strain with a more heat tolerant virus for the 
2015-16 vaccine season.  However, the LAIV issue clearly has implications for the results of the 
present study comparing IIV an LAIV for 2014-15 season. The assays assessing evaluation 
antibody responses elicited by LAIV vaccination demonstrated little to no response against the 
H1N1 stain.  It will be necessary to evaluate an additional vaccine year prior to making any firm 
conclusions about LAIV given these unexpected complications.   
Another issue affecting our results could be due to the sensitivity of the assays conducted.  
HAI assays are known to not be the best predictors of antibody responses to LAIV vaccines.  
Because the vaccines are administered intramuscularly (IIV), the use of peripheral blood 
serum/cells was acceptable and assays were developed for ease of use and sample collection.  
However, with the knowledge that influenza is predominantly replicating in a mucosal site, and 
the introduction of a mucosally-administered vaccine (LAIV), serum may not be the most 
effective way to analyze antibody responses to a mucosal infection and/or vaccine.  Further, due 
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to the nasal route of administration, LAIV has a high retention rate in the nasal cavity and 
provides rapid delivery across the mucus membranes of the respiratory tract[22].  
The intramuscular administration of IIV produces variable rates of absorption into the 
blood stream, but can be sustained over extended periods of time [22]. This may make IIV more 
sensitive to antibody responses in serum samples compared to LAIV simply based on the 
different routes of vaccine administration.  It is important to consider the likelihood that LAIV is 
eliciting immune responses in mucosal sites (i.e., lungs) that are not being measure by the 
peripheral blood samples used in HAI and MN assays described here.  Additional assays to 
evaluate mucosal samples (i.e., nasal washes) are warranted and may be more effective in 
evaluating immunogenicity in individuals vaccinated via the mucosal route.  Furthermore, 
consideration should be given to measurement of nasal wash samples in current assays for 
patients receiving LAIV vaccine to test the usefulness of these assays in correlating with mucosal 
responses.  
Overall, protection elicited by the 2014-2015 influenza vaccines was low. The vaccines 
for that season were only 23% effective [23]. On average, vaccine efficacy during a season 
where the vaccine closely matches the circulating influenza virus strains ranges between 50 and 
60% [23]. The pediatric participants who received the IIV, especially those in the 3-8 year old 
cohort, had a better magnitude and breadth of antibody responses against the seasonal circulating 
influenza viruses then the LAIV cohort.  This increased antibody response from day 0 to 21 was 
not expected due to two of the strains in the vaccine not matching the circulating seasonal 
strains, as well as the technical issues encountered with LAIV.  These data lead us to believe that 
past vaccination may play a role in protection for years to come, plainly shows the need for more 
effective influenza vaccines and careful evaluation of same.  
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6.0  FUTURE DIRECTIONS 
These studies highlight the need for better vaccine strategies and for better assays to 
evaluate vaccine immunogenicity and predictors of efficacy.  For the most part, the LAIV 
remains in the nasal cavity once administered, so perhaps analyzing nasal washes rather than 
serum would be a better detection method for antibody response in LAIV.  This study has been 
repeated for the 2015-2016 vaccination season to include a comparison of LAIV to IIV that was 
unable to take place in the current study.  Many of the same Participants from the 2014-15 study 
were recruited in 2015-16.  This is helpful given the importance of prior vaccination found in the 
present study.  It will be interesting to evaluate antibody responses in vaccines without known 
complications.  Finally, the roles of B and T cell responses are being evaluated in both 2014-15 
and 2015-16 vaccine cohorts.  Together these studies will aid in determining which vaccine 
elicits the best antibody response in pediatric participants. 
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